Who are V0034CR01B's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brukinsa, Calquence, MGd, (G) BQ-L14, Acalabrutinib capsule, R-miniCHOP + Acalabrutinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/v0034cr01b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

V0034CR01B — Competitive Intelligence Brief

V0034CR01B (V0034CR01B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BTK inhibitor. Area: Oncology.

phase 3 BTK inhibitor BTK Oncology Small molecule Live · refreshed every 30 min

Target snapshot

V0034CR01B (V0034CR01B) — Pierre Fabre Medicament. This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
V0034CR01B TARGET	V0034CR01B	Pierre Fabre Medicament	phase 3	BTK inhibitor	BTK
Brukinsa	BGB-3111	Beigene Usa Inc	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2019-01-01
Calquence	ACALABRUTINIB	AstraZeneca	marketed	Kinase Inhibitor [EPC]	Tyrosine-protein kinase BTK	2017-01-01
MGd	MGd	Pharmacyclics LLC.	marketed	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
(G) BQ-L14	(G) BQ-L14	National Taiwan University Hospital	marketed	BTK inhibitor	BTK
Acalabrutinib capsule	Acalabrutinib capsule	AstraZeneca	marketed	Bruton's tyrosine kinase (BTK) inhibitor	BTK (Bruton's tyrosine kinase)
R-miniCHOP + Acalabrutinib	R-miniCHOP + Acalabrutinib	Universität des Saarlandes	phase 3	Combination therapy: monoclonal antibody + chemotherapy + BTK inhibitor	CD20 (rituximab component); Bruton tyrosine kinase / BTK (acalabrutinib component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-04-22 — Brukinsa · 10570139 · US
2034-04-22 — Brukinsa · 11142528 · US
2034-04-22 — Brukinsa · 9447106 · US
2037-08-15 — Brukinsa · 11591340 · US
2037-08-15 — Brukinsa · 10927117 · US

Sponsor landscape (BTK inhibitor class)

Acerta Pharma BV · 4 drugs in this class
AstraZeneca · 4 drugs in this class
AbbVie · 2 drugs in this class
Eli Lilly and Company · 1 drug in this class
Fuji Yakuhin Co., Ltd. · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). V0034CR01B — Competitive Intelligence Brief. https://druglandscape.com/ci/v0034cr01b. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab